| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB (OTCGM:IFTBF) through any online brokerage.
There are no as such competitors for INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB.
There is no analysis for INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB to provide a consensus price target.
The stock price for INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB (OTCGM: IFTBF) is $6.85 last updated July 7, 2026 at 1:14 PM EDT.
There are no upcoming dividends for INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB.
INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB does not have any upcoming earnings scheduled.
There is no upcoming split for INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB.
INFANT BACTERIAL AK B ORD by Infant Bacterial Therapeutics AB is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCGM.